Thu, Jul 31, 2014, 3:09 AM EDT - U.S. Markets open in 6 hrs 21 mins

Recent

% | $
Click the to save as a favorite.

EDAP TMS SA Message Board

termi0209 23 posts  |  Last Activity: Jul 29, 2014 2:38 AM Member since: Dec 25, 2010
  • Reply to

    Edap didn´t finish the trial ...???

    by termi0209 Jul 29, 2014 1:52 AM
    termi0209 termi0209 Jul 29, 2014 2:38 AM Flag

    I read all the available info in edap´s website a few days ago , and I found that info..
    I think that there is 0000 problems with the trail, in fact edap joined a few times with the FDA and they followed their recommendations.
    I´m still confident that the adcom will say yes...and it happens...AT LEAST edap will go up 100%..

    Sentiment: Strong Buy

  • Maybe I´m wrong... but reading this P.R I think that we knew that info..
    EDAP Outlines U.S. ENLIGHT Clinical Strategy

    Ablatherm HIFU Trial Update: IDE Submission Expected in 2012

    LYON, France, Apr 26, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (NASDAQ:EDAP), the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics. Based on input from its clinical and regulatory advisors and with concurrence of the Board of Directors, EDAP said it will discontinue enrollment in the Ablatherm-HIFU study in the coming weeks and complete the required 2-year follow-up of all patients treated to that date. The resulting data set, which will include outcomes from more than 100 patients, will form the foundation of a submission to the FDA, which the Company expects to occur in 2012. The Company believes that the submission of data from the patients treated in the U.S. ENLIGHT trial, combined with the strong long-term data in Europe where more than 22,000 Ablatherm-HIFU treatments have been performed to date, and compared with the retrospective clinical data on other therapies from existing registries, will provide a strong clinical profile for FDA evaluation.

    Marc Oczachowski, EDAP's Chief Executive OFFICER, said, "As a Company, we believe there is merit in this strategy as the most practical option to move forward with our U.S. ENLIGHT clinical trial, allowing us to complete the HIFU study in the timeliest possible manner. We believe the data collected from the number of patients that will have been treated in the U.S. with Ablatherm-HIFU represents a valuable asset and, combined wit

    Sentiment: Strong Buy

  • Edap is also developing this technology.it would open a huge market opportunity to them because they could treat multiple cancers.The only avaliable info we can find in Epitarget website ( edap´s partner).
    EDAP to Collaborate on Use of HIFU in Cancer Drug Delivery Following Successful Feasibility Study

    Agreement With Epitarget AS and INSERM

    LYON, France, Nov 2, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today successful completion of feasibility studies aimed at improving delivery of CANCER drugs using a combination of ultrasound sensitive liposomes and High Intensity Focused Ultrasound (HIFU).

    This 3-year EUREKA label research cooperation program between Epitarget AS, a Norwegian Company, French academic laboratory INSERM and EDAP, confirmed that HIFU activates the encapsulated cancer drug doxorubicin after accumulation in solid tumors and thereby facilitates drug delivery. The parties plan to initiate a pre-clinical study to validate safety and efficacy of the innovative approach.

    Research and Development Director, Emmanuel Blanc said, "The completion of this feasibility study marks a pre-clinical milestone as it further demonstrates EDAP's ability to adapt its HIFU technology to new therapeutic applications. Between our extensive experience in focused ultrasound development and INSERM's expertise in HIFU, we are very well positioned to utilize our innovative HIFU technology for such targeted therapeutic approaches.

    Esben A. Nilssen PhD, Epitarget's Chief Executive Officer, said, "Our team is very excited that the demonstration of Epitarget's ultrasound sensitive liposomes in combination with therapeutic ultrasound enhanced the efficacy of established cancer drugs. It provides hope to millions of cancer patients, illustrates the innovative force of cross-functional teams, and fills Epitarget with energy and determination to continue the leading role in this innovative progr

    Sentiment: Strong Buy

  • termi0209 termi0209 Jul 5, 2014 3:21 AM Flag

    Expecting results phase 2 soon..

    EDAP Successfully Completes Preliminary Trial of HIFU in Liver Cancer

    Plan for Second, Larger Trial

    LYON, France, Oct 26, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today successful completion of the first phase of the clinical protocol aimed at evaluating High Intensity Focused Ultrasound (HIFU) technology in patients with metastatic LIVER CANCER. HIFU has the potential to destroy liver tumors through ablation and to reduce bleeding during surgery.

    In an initial preliminary protocol phase, six patients were successfully treated using a newly-developed HIFU tool delivering focused ultrasound to cancerous liver tumors. Clinical results observed fully conformed with those obtained in pre-clinical studies and validated HIFU as being an additional potential option to address liver cancer. More studies need to be implemented and EDAP, together with the clinical team from Lyon-based Centre Leon Berard and INSERM U556, will enter into a second clinical phase that will include a larger number of patients. This study is designed to further validate the performance of this new HIFU instrument in the treatment of liver cancer.

    Pr. Michel Rivoire, Head of Digestive Cancer Surgery Department at Centre Leon Berard, Lyon, commented, "The initial phase of this clinical trial allowed us to confirm safety and efficacy of this new powerful device. All our clinical hypotheses have been confirmed and we were pleased to make these preliminary assessments in less than six months. After validation of these results by an external independent committee, we will begin the second phase of this trial that will be designed to demonstrate the ability and precision of this new tool to fully destroy liver tumors without inducing damage to normal surrounding liver parenchyma."

    Marc Oczachowski, EDAP Chief Executive Officer, added, "We are very pleased with the performance of o

    Sentiment: Strong Buy

  • Reply to

    The game has changed - Here is what I see.

    by daejna Jul 2, 2014 4:13 PM
    termi0209 termi0209 Jul 2, 2014 4:40 PM Flag

    Exactly.The highest close was that day and was 6,3
    That time was my first trade with edap...I had bought a month ago at 3,7..

    Sentiment: Strong Buy

  • Reply to

    The game has changed - Here is what I see.

    by daejna Jul 2, 2014 4:13 PM
    termi0209 termi0209 Jul 2, 2014 4:23 PM Flag

    Good post.
    But the 5 years high price is 6,99, not 5,99 that the stock got before i-move approval at the end of 2010.

  • Reply to

    Looks like a good short here

    by marcus20432 Jun 4, 2014 1:25 PM
    termi0209 termi0209 Jul 2, 2014 4:12 PM Flag

    Are you still alive genius???lol

    Sentiment: Strong Buy

  • Reply to

    what was that 5.75 print

    by krismajp Jul 2, 2014 12:02 PM
    termi0209 termi0209 Jul 2, 2014 12:19 PM Flag

    Amazing! nobody was selling above 3,5 ...with only 3410 shares jumped 20 c...

    12:00:16 5.70 700 NSD
    12:00:16 5.60 2100 NSD
    12:00:16 5.55 1310 BATS
    12:00:16 5.50 100 BATS
    12:00:16 5.50 100 NDD

    Sentiment: Strong Buy

  • Reply to

    5.90

    by vinhhoixuan2000 Jul 1, 2014 10:18 AM
    termi0209 termi0209 Jul 1, 2014 10:25 AM Flag

    You are wrong. 5,9 is not the 5 years high....
    The five years hight is 6,99 and 6,3 the highest close.

    Sentiment: Strong Buy

  • And highest volume in 16 months...BOOOMMM....

    Sentiment: Strong Buy

  • And today another 2 orders of 50 k at the bid at 4,75 and 4,78 that were filled
    Someone is buying.....

    Sentiment: Strong Buy

  • Reply to

    EDAP may be a medical equipment company

    by cuthbertcookie Jun 26, 2014 9:01 PM
    termi0209 termi0209 Jun 30, 2014 3:10 PM Flag

    You can find this info in the Q1 C.C.. in fact the conference was very informative.

    Sentiment: Strong Buy

  • Reply to

    Looking at investing - a couple of concerns

    by stockshock60 Jun 30, 2014 2:31 PM
    termi0209 termi0209 Jun 30, 2014 3:04 PM Flag

    This is one reason and the other reason was:

    http://finance.yahoo.com/news/edap-announces-european-association-urology-123000964.html

    HIFU was experimental untill Q1...

    Sentiment: Strong Buy

  • Reply to

    EDAP needs to surpass $5

    by chase4money Jun 25, 2014 1:28 PM
    termi0209 termi0209 Jun 25, 2014 5:09 PM Flag

    I repeat you ..I,ve been trading edap during last years...and you are wrong again..
    The five years high is not 5,90, at the end of 2010..with the excuse of the i-move approval edap had a huge ran up from 2 to 6,99, and the highest close was 6,3.
    After a surrealist offering at 3,25, when the price was about 5,9 the stock went down ...and after that was absolutly impossible te break 5 $ again...
    But I´m sure that this time will be different and edap will break 5$ in July.
    I´m only commenting it you.....we are in the same boat..and looking for a huge profits..
    Saludos.

    Sentiment: Strong Buy

  • Reply to

    EDAP needs to surpass $5

    by chase4money Jun 25, 2014 1:28 PM
    termi0209 termi0209 Jun 25, 2014 3:07 PM Flag

    Have a look to the chart...I´ve been following this stock during years and like chase said the important point here is 5$...edap has stopped in the past a few times in 5$ ... in fact last year during the ran up edap got 4,94..

    Sentiment: Strong Buy

  • termi0209 termi0209 Jun 25, 2014 3:02 PM Flag

    20 $=496 m dollar m.k .
    With the last offering edap has 24,8 m shares, not 30.

    Sentiment: Strong Buy

  • Reply to

    Sabby again??!!

    by termi0209 Jun 3, 2014 5:38 AM
    termi0209 termi0209 Jun 5, 2014 7:22 AM Flag

    It was very clear. ...Finally time to go up.
    Now we can expect a S.A article very soon.

    Sentiment: Strong Buy

  • Reply to

    Sabby again??!!

    by termi0209 Jun 3, 2014 5:38 AM
    termi0209 termi0209 Jun 3, 2014 8:11 AM Flag

    I have a big position in edap but I can´t deny that this management does very extrange things.
    This situation is vey very sad for shareholders because like you have said a few times after the fantastic news last month and specially the new about the reimbursement ( it only should send the stock to 5$) was absolutly surrealist that the stock couldn´t go up....now looks like that was a big interest to hold edap below 3,5...

    Once this AMAZING deal is done( to sell in the market and to rebuy lower in a offering in the next quarter), we can trust that the next time that the stock try to break 3,5 the result will be different..

    Sentiment: Strong Buy

  • termi0209 by termi0209 Jun 3, 2014 5:38 AM Flag

    Sabby bought last year in the offering at 4$ and it was a big mistake for them, beacuse the offering was made in the last days of May, and a few days before that the company had a meeting with the FDA ( on 3, June), and the company after the meeting said that the next meeting with the FDA would be in 2014 and obviously the stock price dropped.

    They sold their position this year in the Q1, and looks like very clear who was selling big amount of shares all the time about 3,5., and why was impossible to the stock to break 3,5-3,55..

    Now they are buying again at 3,11 in the new offering and recovering part of their losses of the first bought at 4$....and when the stock goes again to 4 $ they´ll have a good profit..
    But the question is...we have had a few positives news in the last month and edap couldn´t break 3,55...was sabby shorting edap because they were expecting to know the date of the meeting for doing a new offering???why not?? is a possibility..

    Vaya banda estos franceses...lol

    Sentiment: Strong Buy

  • Reply to

    FDA panel vote / recommendation ...

    by daejna May 22, 2014 11:37 AM
    termi0209 termi0209 May 22, 2014 11:45 AM Flag

    Probably...edap will be halt...and we´ll know the results the same day after market closes...and edap will trade in A.H...

    Sentiment: Strong Buy

EDAP
3.42-0.27(-7.32%)Jul 30 2:34 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.